ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2030

Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption

Sirisha Sirobhushanam1, Navya Parsa 2, Tamra Reed 1, Celine Berthier 1, Mrinal Sarkar 1, Grace Hile 1, Lam Tsoi 1, Alexander Horswill 3, Johann Gudjonsson 1 and J Michelle Kahlenberg 1, 1University of Michigan, Ann Arbor, MI, 2University of Toledo, Toledo, OH, 3University of Colorado, Denver, CO

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: cutaneous lupus, microbiome and interferons

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background/Purpose: Cutaneous inflammation is recurrent in systemic lupus erythematosus (SLE) and is often triggered by exposure to ultraviolet B (UVB) light. Type I interferons (IFN) play a critical role in SLE skin inflammation and are increased in non-lesional SLE keratinocytes. Mechanisms that drive cutaneous inflammation in SLE are not well-defined and may involve microbial dysbiosis, an underexplored source of cutaneous IFNs. Staphylococcus aureus, known to induce IFN production, could play a role in cutaneous inflammation in SLE. This study thus evaluated the colonization of lupus skin by S. aureus and the extent to which IFNs drive increased colonization rates by S. aureus.

Methods: Methods: Patients with SLE who fulfilled >4 ACR criteria for diagnosis were recruited from the Michigan Lupus Cohort. Nares, chest, and lupus related skin lesions were swabbed and analyzed for S. aureus colonization. To define the impact of IFNs on S. aureus colonization, we examined the effect of type I and type II IFNs (1000U/ml) on barrier gene expression in N/TERTs (a keratinocyte cell line) by real time quantitative PCR (RT-qPCR). Adhesion and invasion of log-phase S. aureus was assessed using confluent N/TERTs treated with IFNα or IFNγ. Adhered S. aureus were quantified by counting colony forming units (CFUs). Cells were treated with gentamicin (200 μg/ml) for invasion assays prior to CFU quantification. Keratinocytes were exposed to baricitinib (10 μg/ml) prior to IFN exposure to block IFN signaling. Primary keratinocytes were isolated from non-lesional skin of SLE patients and matched healthy adults and utilized for RNA-seq analysis as well as adhesion and invasion assays.

Results: Results: We show here that active lupus lesions are highly colonized (~50%) by S. aureus. Microarray data from SLE lesional skin revealed lower expression of various cutaneous barrier genes such as filaggrin (FLG). IFN-exposed keratinocytes demonstrated lower expression of barrier related genes such as FLG, loricrin and involucrin. This repression of barrier genes was also seen in primary SLE keratinocytes without additional IFN treatment via RNA-seq. We next examined the role of IFN exposure on S. aureus colonization by adhesion and invasion assays. S. aureus adherence was significantly higher in keratinocytes that were exposed to IFNα but not IFNγ. RT-qPCR analysis showed higher expression of α-integrin in IFNα but not IFNγ exposed keratinocytes, indicating a possible mechanism for higher S. aureus adherence. In addition, IFNγ exposure appeared to inhibit invasion of S. aureus into keratinocytes. Confirming a role for IFNs in primary cells, S. aureus adhered better to SLE keratinocytes than healthy control keratinocytes. Exposure to baricitinib reduced IFNα-promoted S. aureus adherence, thus confirming specificity of the IFN activity.

Conclusion: Conclusion: SLE lesional skin is highly colonized by S. aureus and exhibits lower barrier gene expression indicating barrier compromise. IFN exposure inhibits barrier gene expression and IFNα promotes S. aureus adhesion. Together, these data suggest that chronic exposure to IFNs induces barrier disruption that allows for higher S. aureus colonization in SLE skin.


Disclosure: S. Sirobhushanam, None; N. Parsa, None; T. Reed, None; C. Berthier, None; M. Sarkar, None; G. Hile, None; L. Tsoi, None; A. Horswill, None; J. Gudjonsson, AbbVie, 2, Genentech, 2, genentech, 2, MiRagen, 5, Novartis, 5, Sun Pharma, 2, SunPharma, 2; J. Kahlenberg, AstraZeneca, 5, Bristol Myers Squibb, 5, Eli Lilly, 5.

To cite this abstract in AMA style:

Sirobhushanam S, Parsa N, Reed T, Berthier C, Sarkar M, Hile G, Tsoi L, Horswill A, Gudjonsson J, Kahlenberg J. Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/staphylococcus-aureus-colonization-is-increased-on-lupus-skin-lesions-and-is-promoted-by-interferon-mediated-barrier-disruption/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/staphylococcus-aureus-colonization-is-increased-on-lupus-skin-lesions-and-is-promoted-by-interferon-mediated-barrier-disruption/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology